RESUMEN

Introduction: Hereditary forms of intellectual disability (ID), an estimated prevalence ranging between 1% and 3% in the general population, are among the most important problems in health care. Especially, autosomal-recessive ID has a very heterogeneous molecular basis and a lack of specific phenotypic features. Methods: Here, we report on two unrelated patients with autosomal-recessive ID, microcephaly, and autistic features and review the patients with TRAPPC9-related ID. Whole-exome sequencing and array CGH were performed for molecular diagnosis of the patients. Results: The first case has a microdeletion on chromosome 8q24.23-q24.3 region which is 1.7 Mb in length and includes the last 5 exons of TRAPPC9, and c.3435delG [p.Thr1146Profs*8] deletion. The second case has a homozygous missense c.623A>C (p.His208Pro) variant in TRAPPC9 which is detected by means of whole-exome sequencing study of the proband. We also reviewed the clinical findings and mutation spectrum of all patients with TRAPPC9-related ID reported so far. Conclusions: Our study showed that the most consistent clinical findings for TRAPPC9-related ID are ID, microcephaly, and some structural brain MRI abnormalities. The mutations in the TRAPPC9 are scattered throughout all exons of TRAPPC9 indicating there is no hot spot mutation region in this gene.

Asunto(s)

Anomalías Múltiples , Discapacidad Intelectual , Micrognatismo , Humanos , Mosaicismo , Anomalías Múltiples/diagnóstico , Anomalías Múltiples/genética , Discapacidad Intelectual/diagnóstico , Discapacidad Intelectual/genética , Micrognatismo/diagnóstico , Micrognatismo/genética , Proteínas de Unión al ADN/genética , Factores de Transcripción/genética

RESUMEN

AIM: To determine the effects of valproate (VPA), carbamazepine (CBZ), oxcarbazepine (OXC), topiramate (TPM), lamotrigine (LTG), and levetiracetam (LEV) on ovarian folliculogenesis in young rats. METHODS: Forty-nine female Wistar rats, aged 21-24 days, were divided equally into 7 experimental groups. These were given tap water over 21-24 days (control group), 300 mg/kg of VPA, 150 mg/kg of CBZ, 150 mg/kg of OXC, 100 mg/kg of TPM, 10 mg/kg of LTG, or 50 mg/kg of LEV daily in 2 doses via oral gavage until the end of puberty. At the end of the study, the estrous cycle of each rat was monitored daily, and those rats in pro-estrus or di-estrus were sacrificed and the ovaries removed. Serial sections obtained from the ovaries were stained with hematoxylin and eosin, and the corpora lutea and follicles were enumerated. Apoptotic cells were detected using the TUNEL technique. Various serial sections were immunohistochemically stained with proliferating cell nuclear antigen (PCNA), growth differentiation factor (GDF)-9, caspase-3, caspase-9, transforming growth factor beta 1 (TGF-1), and epidermal growth factor (EGF), and evaluated and photographed under a light microscope. KEY FINDINGS: The number of corpora lutea was significantly increased in the VPA, CBZ, OXC, and LTG groups compared to the control group (p < 0.001). The number of TUNEL-positive ovarian follicles was 3.3 ± 1.1 (median, 3), 6.1 ± 0.9 (median, 6), and 5.7 ± 0.8 (median,6) in the control, OXC and LEV groups, respectively (p < 0.001). The number of TUNEL-positive granulosa cells was higher in all the groups treated with antiepileptics, with the exception of the TPM group, compared to the control group (p < 0.001). HSCOREs for immunohistochemical staining using PCNA, GDF-9, TGF-1 and EGF were significantly higher in the control group than in the others (p < 0.001). HSCORE for staining using caspase-3 was significantly higher in the VPA, CBZ, OXC and LEV groups, while the HSCORE was significantly lower in the TPM group than in the control group. HSCORE for staining using caspase-9 was significantly higher in the VPA, CBZ and OXC groups, while it was significantly lower in the TPM group than in the control group (p < 0.001). SIGNIFICANCE: Exposure to VPA, CBZ, OXC, TPM, LTG and LEV caused different levels of impaired folliculogenesis in young rats.

Asunto(s)

Anticonvulsivantes , Ácido Valproico , Animales , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Benzodiazepinas/farmacología , Carbamazepina/farmacología , Carbamazepina/uso terapéutico , Caspasa 3 , Caspasa 9/farmacología , Factor de Crecimiento Epidérmico/farmacología , Femenino , Lamotrigina/farmacología , Levetiracetam/farmacología , Ovario , Oxcarbazepina , Antígeno Nuclear de Célula en Proliferación/farmacología , Ratas , Ratas Wistar , Topiramato/farmacología , Ácido Valproico/farmacología , Ácido Valproico/uso terapéutico

RESUMEN

OBJECTIVES: Congenital disorders of glycosylation (CDGs) are rare inherited metabolic disorders associated with facial dysmorphism and in the majority of the patients, there is an important neurological impairment. Epilepsy was a main concern in rare forms of the disease. There are two groups of the disease: CDG-I results from the defects in glycan addition to the N-terminal and CDG-II occurs due to defects in the processing of protein bound glycans. SLC35A2-CDG is a rare form of CDG caused by mutations in the X-linked gene that encodes a UDP-Galactose transporter. The manifestations of the disease include seizures, failure to thrive, delayed myelination, and cerebral atrophy. CASE PRESENTATION: We describe herein a severe female child with intractable seizures, microcephaly, growth retardation, hypotonia, global developmental delay, facial dysmorphism, skeletal findings, cerebral/cerebellar atrophy, and thin corpus callosum, and a mildly affected male carrying a novel variant with seizures and mild global developmental delay who were found by whole exome sequencing (WES) for SLC35A2 mutations previously not reported. CONCLUSIONS: Our findings expand the number of reported cases and add novel variants to the repertoire of SLC35A2-CDG.

Asunto(s)

Anomalías Múltiples/patología , Trastornos Congénitos de Glicosilación/patología , Epilepsia/patología , Proteínas de Transporte de Monosacáridos/genética , Mutación , Convulsiones/patología , Anomalías Múltiples/genética , Preescolar , Trastornos Congénitos de Glicosilación/complicaciones , Trastornos Congénitos de Glicosilación/genética , Epilepsia/complicaciones , Epilepsia/genética , Femenino , Humanos , Masculino , Pronóstico , Convulsiones/complicaciones , Convulsiones/genética

RESUMEN

Inositol polyphosphates are vital metabolic and secondary messengers, involved in diverse cellular functions. Therefore, tight regulation of inositol polyphosphate metabolism is essential for proper cell physiology. Here, we describe an early-onset neurodegenerative syndrome caused by loss-of-function mutations in the multiple inositol-polyphosphate phosphatase 1 gene (MINPP1). Patients are found to have a distinct type of Pontocerebellar Hypoplasia with typical basal ganglia involvement on neuroimaging. We find that patient-derived and genome edited MINPP1-/- induced stem cells exhibit an inefficient neuronal differentiation combined with an increased cell death. MINPP1 deficiency results in an intracellular imbalance of the inositol polyphosphate metabolism. This metabolic defect is characterized by an accumulation of highly phosphorylated inositols, mostly inositol hexakisphosphate (IP6), detected in HEK293 cells, fibroblasts, iPSCs and differentiating neurons lacking MINPP1. In mutant cells, higher IP6 level is expected to be associated with an increased chelation of intracellular cations, such as iron or calcium, resulting in decreased levels of available ions. These data suggest the involvement of IP6-mediated chelation on Pontocerebellar Hypoplasia disease pathology and thereby highlight the critical role of MINPP1 in the regulation of human brain development and homeostasis.

Asunto(s)

Enfermedades Cerebelosas/metabolismo , Quelantes/metabolismo , Citoplasma/metabolismo , Monoéster Fosfórico Hidrolasas/metabolismo , Ácido Fítico/metabolismo , Animales , Muerte Celular , Diferenciación Celular , Enfermedades Cerebelosas/diagnóstico por imagen , Enfermedades Cerebelosas/patología , Niño , Preescolar , Femenino , Técnicas de Inactivación de Genes , Células HEK293 , Homeostasis , Humanos , Lactante , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Mutación , Trastornos del Neurodesarrollo/metabolismo , Monoéster Fosfórico Hidrolasas/genética , Monoéster Fosfórico Hidrolasas/farmacología , Fosforilación , Células Madre/efectos de los fármacos , Transcriptoma

RESUMEN

We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels. The patient presented with lethargy, hyperthermia, generalized tremor and rigidity with normal serum CK levels. After cessation of risperidone and adding clonezepam to the supportive treatment, symptoms of NMS were ameliorated. We conclude that although serum CK elevation is a useful indicator for the early detection of NMS, normal serum CK levels may be seen during the NMS course in the presence of GAMT deficiency.

Asunto(s)

Creatina Quinasa/sangre , Antagonistas de Dopamina/efectos adversos , Guanidinoacetato N-Metiltransferasa/deficiencia , Trastornos del Desarrollo del Lenguaje/tratamiento farmacológico , Trastornos del Movimiento/congénito , Síndrome Neuroléptico Maligno/sangre , Risperidona/efectos adversos , Niño , Humanos , Masculino , Trastornos del Movimiento/tratamiento farmacológico , Síndrome Neuroléptico Maligno/diagnóstico

RESUMEN

Aydin HI, Sönmez FM. A novel mutation in two cousins with guanidinoacetate methyltransferase (GAMT) deficiency presented with autism. Turk J Pediatr 2019; 61: 92-96. Guanidinoacetate methyltransferase (GAMT) deficiency is a rare autosomal recessive disorder of creatine biosynthesis. Here, we report 9 and 10-year-old cousins with GAMT deficiency caused by a novel mutation who both exhibited neurodevelopmental retardation, seizures, behavioral problems, and autism that began during early infancy. The patients were diagnosed as having only autism and followed for years without a specific diagnosis although they had very low levels of serum creatinine for several times. A novel nonsense mutation in the GAMT gene that caused cessation of synthesis of the protein encoded by this gene was identified in these patients. GAMT deficiency is a treatable inborn error of metabolism and should be considered for all patients with hypotonia, developmental delay, seizures and autism, particularly if low serum creatinine levels are observed.

Asunto(s)

Trastorno Autístico/genética , Codón sin Sentido , Guanidinoacetato N-Metiltransferasa/deficiencia , Trastornos del Desarrollo del Lenguaje/diagnóstico , Trastornos del Desarrollo del Lenguaje/genética , Trastornos del Movimiento/congénito , Niño , Creatinina/sangre , Discapacidades del Desarrollo/genética , Femenino , Guanidinoacetato N-Metiltransferasa/genética , Humanos , Masculino , Trastornos del Movimiento/diagnóstico , Trastornos del Movimiento/genética , Hipotonía Muscular/genética , Convulsiones/genética

RESUMEN

Ciliopathies are clinical disorders of the primary cilium with widely recognized phenotypic and genetic heterogeneity. In two Arab consanguineous families, we mapped a ciliopathy phenotype that most closely matches Joubert syndrome (hypotonia, developmental delay, typical facies, oculomotor apraxia, polydactyly, and subtle posterior fossa abnormalities) to a single locus in which a founder homozygous truncating variant in FAM149B1 was identified by exome sequencing. We subsequently identified a third Arab consanguineous multiplex family in which the phenotype of Joubert syndrome/oral-facial-digital syndrome (OFD VI) was found to co-segregate with the same founder variant in FAM149B1. Independently, autozygosity mapping and exome sequencing in a consanguineous Turkish family with Joubert syndrome highlighted a different homozygous truncating variant in the same gene. FAM149B1 encodes a protein of unknown function. Mutant fibroblasts were found to have normal ciliogenesis potential. However, distinct cilia-related abnormalities were observed in these cells: abnormal accumulation IFT complex at the distal tips of the cilia, which assumed bulbous appearance, increased length of the primary cilium, and dysregulated SHH signaling. We conclude that FAM149B1 is required for normal ciliary biology and that its deficiency results in a range of ciliopathy phenotypes in humans along the spectrum of Joubert syndrome.

Asunto(s)

Anomalías Múltiples/genética , Cerebelo/anomalías , Cilios/patología , Ciliopatías/diagnóstico , Ciliopatías/genética , Proteínas del Citoesqueleto/genética , Anomalías del Ojo/genética , Enfermedades Renales Quísticas/genética , Mutación , Retina/anomalías , Adolescente , Alelos , Preescolar , Cilios/genética , Consanguinidad , Exoma , Genes Recesivos , Homocigoto , Humanos , Masculino , Malformaciones del Sistema Nervioso/genética , Síndromes Orofaciodigitales/genética , Fenotipo , Análisis de Secuencia de ADN , Transducción de Señal , Turquía

RESUMEN

Reported here are twins, both of whom have a 1q21.3 microdeletion and who exhibit key features common to previously reported cases such as microcephaly and developmental delay. However, some clinical findings and deleted genes differed from those in previously reported cases. The karyotype was normal 46, XX for both of the twins. Array comparative genomic hybridization (CGH) identified a 2.6 Mb deletion on chromosome 1q21.3 (chr1: 153,514,121-156,171,335 bp) in case 1 and a 1.6 Mb deletion on chromosome 1q21.3 (chr1: 154,748,365-156,358,923 bp) in case 2. The deleted region includes DPM3, MUC1, GBA, PKLR, RIT1, and LAMTOR2 in both siblings. To the extent known, this is the second report of a 1q21.3 microdeletion in a family with mental retardation, developmental delay, seizures, and some dysmorphic features, thus expanding the phenotypic spectrum.

RESUMEN

Autism spectrum disorders (ASD) are a group of genetic disorders often overlapping with other neurological conditions. We previously described abnormalities in the branched-chain amino acid (BCAA) catabolic pathway as a cause of ASD. Here, we show that the solute carrier transporter 7a5 (SLC7A5), a large neutral amino acid transporter localized at the blood brain barrier (BBB), has an essential role in maintaining normal levels of brain BCAAs. In mice, deletion of Slc7a5 from the endothelial cells of the BBB leads to atypical brain amino acid profile, abnormal mRNA translation, and severe neurological abnormalities. Furthermore, we identified several patients with autistic traits and motor delay carrying deleterious homozygous mutations in the SLC7A5 gene. Finally, we demonstrate that BCAA intracerebroventricular administration ameliorates abnormal behaviors in adult mutant mice. Our data elucidate a neurological syndrome defined by SLC7A5 mutations and support an essential role for the BCAA in human brain function.

Asunto(s)

Trastorno del Espectro Autista/genética , Barrera Hematoencefálica/fisiopatología , Transportador de Aminoácidos Neutros Grandes 1/metabolismo , Mutación , Aminoácidos/administración & dosificación , Aminoácidos/metabolismo , Animales , Trastorno del Espectro Autista/metabolismo , Trastorno del Espectro Autista/patología , Trastorno del Espectro Autista/fisiopatología , Encéfalo/metabolismo , Encéfalo/patología , Encéfalo/fisiopatología , Femenino , Humanos , Lactante , Recién Nacido , Transportador de Aminoácidos Neutros Grandes 1/genética , Masculino , Ratones , Ratones Noqueados , Linaje , Biosíntesis de Proteínas , Receptor TIE-2/genética

RESUMEN

Coffin-Siris syndrome (CSS) (MIM 135900) is characterized by developmental delay, severe speech impairment, distinctive facial features, hypertrichosis, aplasia or hypoplasia of the distal phalanx or nail of the fifth digit and agenesis of the corpus callosum. Recently, it was shown that mutations in the ARID1B gene are the main cause of CSS, accounting for 76% of identified mutations. Here, we report a 15 year-old female patient who was admitted to our clinic with seizures, speech problems, dysmorphic features, bilaterally big, large thumb, café-au-lait (CAL) spots, obesity and hyperinsulinism. First, the patient was thought to have an association of neurofibromatosis and Rubinstein Taybi syndrome. Because of the large size of the NF1 gene for neurofibromatosis and CREBBP gene for Rubinstein Taybi syndrome, whole exome sequence analysis (WES) was conducted and a novel ARID1B mutation was identified. The proband WES test identified a novel heterozygous frameshift mutation c.3394_3395insTA in exon 13 of ARID1B (NM_017519.2) predicting a premature stop codon p.(Tyr1132Leufs*67). Sanger sequencing confirmed the heterozygous c.3394_3395insTA mutation in the proband and that it was not present in her parents indicating de novo mutation. Further investigation and new cases will help to understand this phenomenon better.

RESUMEN

Several studies have shown a link between vitamin D deficiency and epilepsy. This study includes 60 newly diagnosed idiopathic epilepsy patients and 101 healthy controls (between the ages of 5 and 16). Each group was also divided into two subgroups according to seasonal changes in terms of months of longer versus shorter daylight. We retrospectively evaluated the levels of calcium, phosphorus, alkaline phosphatase, parathyroid hormone, and 25-OH vitamin-D3 in the study participants. Levels below 20 ng/ml were defined as vitamin D deficiency and levels of 20-30 ng/ml as insufficiency. There were no significant differences in age, gender distribution and levels of calcium, phosphorus, alkaline phosphatase and parathyroid hormone between the groups. The level of 25-OH vitamin-D3 in the patient group was significantly lower when compared to the control group (p < 0.05) (14.07 ± 8.12 and 23.38 ± 12.80 ng/ml, respectively). This difference also held true when evaluation was made according to seasonal evaluation (12.38 ± 6.53 and 17.64 ± 1.14 in shorter daylight and 18.71 ± 9.87 and 30.82 ± 1.04 in longer daylight).

Asunto(s)

Epilepsia/epidemiología , Deficiencia de Vitamina D/epidemiología , Adolescente , Huesos/metabolismo , Encéfalo/fisiopatología , Niño , Preescolar , Electroencefalografía , Epilepsia/fisiopatología , Femenino , Humanos , Masculino , Fotoperiodo , Estudios Retrospectivos , Estaciones del Año , Convulsiones/fisiopatología , Espectrofotometría , Deficiencia de Vitamina D/fisiopatología

RESUMEN

Marinesco-Sjögren syndrome is a rare autosomal recessive multisystem disorder featuring cerebellar ataxia, early-onset cataracts, chronic myopathy, variable intellectual disability and delayed motor development. More recently, mutations in the SIL1 gene, which encodes an endoplasmic reticulum resident co-chaperone, were identified as the main cause of Marinesco-Sjögren syndrome. Here we describe the results of SIL1 mutation analysis in 62 patients presenting with early-onset ataxia, cataracts and myopathy or combinations of at least two of these. We obtained a mutation detection rate of 60% (15/25) among patients with the characteristic Marinesco-Sjögren syndrome triad (ataxia, cataracts, myopathy) whereas the detection rate in the group of patients with more variable phenotypic presentation was below 3% (1/37). We report 16 unrelated families with a total of 19 different SIL1 mutations. Among these mutations are 15 previously unreported changes, including single- and multi-exon deletions. Based on data from our screening cohort and data compiled from the literature we found that SIL1 mutations are invariably associated with the combination of a cerebellar syndrome and chronic myopathy. Cataracts were observed in all patients beyond the age of 7 years, but might be missing in infants. Six patients with SIL1 mutations had no intellectual disability, extending the known wide range of cognitive capabilities in Marinesco-Sjögren syndrome to include normal intelligence. Modestly constant features were somatic growth retardation, skeletal abnormalities and pyramidal tract signs. Examination of mutant SIL1 expression in cultured patient lymphoblasts suggested that SIL1 mutations result in severely reduced SIL1 protein levels irrespective of the type and position of mutations. Our data broaden the SIL1 mutation spectrum and confirm that SIL1 is the major Marinesco-Sjögren syndrome gene. SIL1 patients usually present with the characteristic triad but cataracts might be missing in young children. As cognitive impairment is not obligatory, patients without intellectual disability but a Marinesco-Sjögren syndrome-compatible phenotype should receive SIL1 mutation analysis. Despite allelic heterogeneity and many families with private mutations, the phenotype related to SIL1 mutations is relatively homogenous. Based on SIL1 expression studies we speculate that this may arise from a uniform effect of different mutations on protein expression.

Asunto(s)

Factores de Intercambio de Guanina Nucleótido/genética , Mutación/genética , Degeneraciones Espinocerebelosas/genética , Adolescente , Linfocitos B , Encéfalo/patología , Encéfalo/ultraestructura , Células Cultivadas , Análisis Mutacional de ADN , Salud de la Familia , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Músculo Esquelético/patología , Músculo Esquelético/ultraestructura , Estudios Retrospectivos , Degeneraciones Espinocerebelosas/patología , Degeneraciones Espinocerebelosas/fisiopatología

RESUMEN

Frequent headache is a symptom that leads to significant distress and functional impairment, both in childhood and in adulthood. Some medical conditions are associated with a higher frequency of headaches. Borderline cerebellar tonsillar ectopia which may be defined as the downward extension of cerebellar tonsils of <5 mm below the foramen magnum is among these conditions. Although questions persist about the clinical significance of this rare entity on headache, there are studies reporting severe headache syndrome in 16% of these patients. We report a 9-year old male patient, who presented to our clinic with a frontal headache of 5 years' duration, and was found to have borderline cerebellar tonsillar ectopia on magnetic resonance imaging. To the best of our knowledge, there has not been a reported case of this coexistence at this early stage of life. We would like to contribute to the literature, owing to the very rare and atypical presentation of this entity in the early childhood period.

Asunto(s)

Enfermedades Cerebelosas/diagnóstico , Coristoma/diagnóstico , Tonsila Palatina , Enfermedades Cerebelosas/complicaciones , Niño , Coristoma/complicaciones , Cefalea/etiología , Humanos , Masculino

RESUMEN

PURPOSE: Antiepileptic drugs may affect the endocrine system. We investigated the effects of valproic acid and topiramate on the levels of insulin, c-peptide and adipocytokines in pre-pubertal patients with idiopathic partial and generalized epilepsy. METHODS: Forty-one children with epilepsy were included. The patients were divided into two groups (valproic acid; n = 21, topiramate; n = 20). The weight, height, body mass index and homeostasis model assessment of insulin resistance (HOMA-IR) were recorded and insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin and resistin levels were determined at 0, 6 and 12 months of therapy. RESULTS: In the valproate group, weight and height increased significantly. Seven of 21 patients were overweight at the end of one year. Leptin was higher in the overweight subgroup. Although insulin and HOMA-IR increased (p < 0.05), none of the patients showed hyperinsulinism or IR. Resistin had decreased at the 6th and 12th months (p < 0.05). In the topiramate group, some statistically nonsignificant changes were demonstrated. CONCLUSION: The mechanisms behind valproate and topiramate-related weight control are still unclear, especially in children. Valproate and topiramate affect the weight, BMI, and insulin, leptin and adipocytokine levels in prepubertal children. We suggest that further studies including more patients with a long follow-up period are necessary to draw a firm conclusion regarding an association between the treatment with these drugs and the levels of leptin, insulin and adipocytokines.

Asunto(s)

Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Fructosa/análogos & derivados , Ácido Valproico/uso terapéutico , Adiponectina/sangre , Anticonvulsivantes/farmacología , Índice de Masa Corporal , Peso Corporal/efectos de los fármacos , Péptido C/sangre , Niño , Epilepsia/sangre , Femenino , Fructosa/farmacología , Fructosa/uso terapéutico , Humanos , Insulina/sangre , Leptina/sangre , Masculino , Neuropéptido Y/sangre , Nicotinamida Fosforribosiltransferasa/sangre , Resistina/sangre , Topiramato , Ácido Valproico/farmacología

RESUMEN

La cefalea es un síntoma que conlleva un malestar signifcativo y deterioro funcional en quienes lo sufren con frecuencia, tanto en la infancia como en la edad adulta. Algunas afecciones se asocian con una mayor frecuencia de cefaleas. La ectopia amigdalina cerebelosa borderline, defnida como la protrusión de las amígdalas cerebelosas por foramen magnum), es una de esas afecciones. Aunque no está claro el signifcado clínico de esta entidad como causa de cefalea, hay estudios que informaron su asociación en el 16% de los pacientes. Se presenta el caso de un paciente de 9 años que acudió a la consulta por padecer una cefalea frontal de 5 años de evolución. Se diagnosticó ectopia amigdalina cerebelosa borderline mediante una resonancia magnética. Se describe este caso dado lo atípico de la presentación de esta entidad en la infancia.(AU)

---

Frequent headache is a symptom that leads to signifcant distress and functional impairment, both in childhood and in adulthood. Some medical conditions are associated with a higher frequency of headaches. Borderline cerebellar tonsillar ectopia which may be defned as the downward extension of cerebellar tonsils of < 5 mm below the foramen magnum is among these conditions. Although questions persist about the clinical signifcance of this rare entity on headache, there are studies reporting severe headache syndrome in 16% of these patients. We report a 9-year old male patient, who presented to our clinic with a frontal headache of 5 years duration, and was found to have borderline cerebellar tonsillar ectopia on magnetic resonance imaging. To the best of our knowledge, there has not been a reported case of this coexistence at this early stage of life. We would like to contribute to the literature, owing to the very rare and atypical presentation of this entity in the early childhood period.(AU)

Asunto(s)

Niño , Humanos , Masculino , Enfermedades Cerebelosas/diagnóstico , Coristoma/diagnóstico , Tonsila Palatina , Enfermedades Cerebelosas/complicaciones , Coristoma/complicaciones , Cefalea/etiología

RESUMEN

La cefalea es un síntoma que conlleva un malestar signifcativo y deterioro funcional en quienes lo sufren con frecuencia, tanto en la infancia como en la edad adulta. Algunas afecciones se asocian con una mayor frecuencia de cefaleas. La ectopia amigdalina cerebelosa borderline, defnida como la protrusión de las amígdalas cerebelosas por foramen magnum), es una de esas afecciones. Aunque no está claro el signifcado clínico de esta entidad como causa de cefalea, hay estudios que informaron su asociación en el 16% de los pacientes. Se presenta el caso de un paciente de 9 años que acudió a la consulta por padecer una cefalea frontal de 5 años de evolución. Se diagnosticó ectopia amigdalina cerebelosa borderline mediante una resonancia magnética. Se describe este caso dado lo atípico de la presentación de esta entidad en la infancia.

---

Frequent headache is a symptom that leads to signifcant distress and functional impairment, both in childhood and in adulthood. Some medical conditions are associated with a higher frequency of headaches. Borderline cerebellar tonsillar ectopia which may be defned as the downward extension of cerebellar tonsils of < 5 mm below the foramen magnum is among these conditions. Although questions persist about the clinical signifcance of this rare entity on headache, there are studies reporting severe headache syndrome in 16% of these patients. We report a 9-year old male patient, who presented to our clinic with a frontal headache of 5 years' duration, and was found to have borderline cerebellar tonsillar ectopia on magnetic resonance imaging. To the best of our knowledge, there has not been a reported case of this coexistence at this early stage of life. We would like to contribute to the literature, owing to the very rare and atypical presentation of this entity in the early childhood period.

Asunto(s)

Niño , Humanos , Masculino , Enfermedades Cerebelosas/diagnóstico , Coristoma/diagnóstico , Tonsila Palatina , Enfermedades Cerebelosas/complicaciones , Coristoma/complicaciones , Cefalea/etiología

RESUMEN

PURPOSE: Antiepileptic drugs have been reported to reduce the levels of serum immunoglobulins and affect the production and levels of certain cytokines. We investigated the effects of valproic acid (VPA) and topiramate (TPM) on the blood levels of interleukin (IL)-1α, IL-1ß, IL-6, IL-10, and TNF-α in children with idiopathic generalized and partial epilepsy. METHODS: Forty prepubertal children aged 6-12 (mean 8.3±1.7) years, 19/40 (47.5%) female and 21/40 (52.5%) male, with idiopathic generalized or partial epilepsy diagnosed in the child neurology outpatient clinic were included. The patients were divided into two treatment groups: 20 were treated with VPA and 20 with TPM. The plasma levels of IL-1α, IL-1ß, IL-6, IL-10, TNF-α were measured using ELISA method before the initiation of treatment and at the 6th and 12th months of the treatment. The Chi-square test was used to compare qualitative data. To compare the periods, recurrence measurements were done using variance analysis and Freidman 2-sided variance analysis. p<0.05 was considered as statistically significant. RESULTS: In the VPA group, the levels of IL-1α significantly increased at 12 months while the levels of IL-10 decreased at 6 months of treatment compared to values before treatment (p<0.05). There was no significant difference in levels of IL-1ß, IL-6, TNF-α (p>0.05). In the TPM group, lower levels of IL-10 were observed at 6th and 12th months compared to the onset of treatment (p<0.05). CONCLUSION: The results of this study demonstrated that VPA and TPM might lead to changes in the levels of cytokines in epileptic patients. The next step would be to investigate the relation of these findings to the outcome of epilepsy and response to treatment.

Asunto(s)

Citocinas/sangre , Epilepsias Parciales/sangre , Epilepsia Generalizada/sangre , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/uso terapéutico , Distribución de Chi-Cuadrado , Niño , Progresión de la Enfermedad , Electroencefalografía , Ensayo de Inmunoadsorción Enzimática , Epilepsias Parciales/tratamiento farmacológico , Epilepsia Generalizada/tratamiento farmacológico , Femenino , Fructosa/efectos adversos , Fructosa/análogos & derivados , Fructosa/uso terapéutico , Humanos , Imagen por Resonancia Magnética , Masculino , Topiramato , Ácido Valproico/efectos adversos , Ácido Valproico/uso terapéutico

RESUMEN

Pontocerebellar hypoplasia consists of a rare heterogeneous group of congenital neurodevelopmental disorders characterized by hypoplasia and atrophy of the cerebellar cortex, dentate and pontine nuclei, and inferior olives. The very low density lipoprotein receptor protein is an integral part of the reelin signaling pathway, which guides neuroblast migration in the cerebral cortex and cerebellum. Mutations in this receptor cause nonprogressive cerebellar ataxia, mental retardation, and cerebellar hypoplasia. In this report, we present 3 patients from 2 different families displaying very low density lipoprotein receptor-associated pontocerebellar hypoplasia, cortical dysplasia, mental retardation, and bipedal gait. One of the siblings has also displayed dysmorphic features, as we previously reported before the identification of the genetic defect in this family.

Asunto(s)

Encéfalo/anomalías , Discapacidad Intelectual/genética , Malformaciones del Desarrollo Cortical/genética , Mutación , Atrofias Olivopontocerebelosas/genética , Receptores de LDL/genética , Adulto , Atrofia/patología , Encéfalo/patología , Preescolar , Femenino , Humanos , Discapacidad Intelectual/patología , Imagen por Resonancia Magnética , Masculino , Malformaciones del Desarrollo Cortical/patología , Atrofias Olivopontocerebelosas/patología , Proteína Reelina , Hermanos , Turquía

RESUMEN

Although cerebral sinovenous thrombosis (CSVT) is a rare condition in the neonatal period, high rates of morbidity and mortality necessitate the establishment of an early diagnosis. Methylenetetrahydrofolate reductase (MTHFR) plays a central role in the folate cycle and mutations of MTHFR are associated with vascular disease. While the C677T common missense mutation is the most well-defined MTHFR polymorphism, another common missense mutation, A1298C also exists. There has been no reported case of CSVT associated with MTHFR A1298C mutation in the neonatal period. Herein, we report a neonate with CSVT who was found to have MTHFR A1298C homozygosity.

Asunto(s)

Trombosis Intracraneal/diagnóstico , Trombosis Intracraneal/genética , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Mutación Missense/genética , Femenino , Homocigoto , Humanos , Recién Nacido